NEJM: Early Combo Monoclonal Antibody Therapy in COVID-19 NEJM has published the interim analysis of the REGN-COV2 trial, wherein an antibody cocktail reduced viral loads with less clinical consequences. https://t.co/Gdby5qmPNG